Vor Biopharma (NASDAQ:VOR) Major Shareholder Sells $2,287,227.60 in Stock

Vor Biopharma Inc. (NASDAQ:VOR) major shareholder Reprogrammed Interchange Llc sold 71,655 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $31.92, for a total transaction of $2,287,227.60. Following the sale, the insider directly owned 1,206,463 shares in the company, valued at approximately $38,510,298.96. The trade was a 5.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Thursday, October 16th, Reprogrammed Interchange Llc sold 2,021 shares of Vor Biopharma stock. The shares were sold at an average price of $30.45, for a total transaction of $61,539.45.
• On Tuesday, October 14th, Reprogrammed Interchange Llc sold 33,668 shares of Vor Biopharma stock. The stock was sold at an average price of $30.32, for a total transaction of $1,020,813.76.
• On Monday, October 13th, Reprogrammed Interchange Llc sold 22,006 shares of Vor Biopharma stock. The shares were sold at an average price of $32.44, for a total transaction of $713,874.64.
• On Friday, October 10th, Reprogrammed Interchange Llc sold 40,983 shares of Vor Biopharma stock. The shares were sold at an average price of $30.97, for a total transaction of $1,269,243.51.
• On Thursday, October 9th, Reprogrammed Interchange Llc sold 48,884 shares of Vor Biopharma stock. The stock was sold at an average price of $32.07, for a total value of $1,567,709.88.
• On Wednesday, October 8th, Reprogrammed Interchange Llc sold 75,262 shares of Vor Biopharma stock. The shares were sold at an average price of $33.87, for a total value of $2,549,123.94.
• On Tuesday, October 7th, Reprogrammed Interchange Llc sold 27,624 shares of Vor Biopharma stock. The shares were sold at an average price of $33.84, for a total value of $934,796.16.
• On Monday, October 6th, Reprogrammed Interchange Llc sold 70,763 shares of Vor Biopharma stock. The stock was sold at an average price of $37.01, for a total value of $2,618,938.63.
• On Friday, October 3rd, Reprogrammed Interchange Llc sold 7,901 shares of Vor Biopharma stock. The shares were sold at an average price of $37.83, for a total value of $298,894.83.
• On Thursday, October 2nd, Reprogrammed Interchange Llc sold 32,451 shares of Vor Biopharma stock. The shares were sold at an average price of $39.83, for a total value of $1,292,523.33.

Vor Biopharma Stock Down 0.2%

Shares of Vor Biopharma stock opened at $29.00 on Monday. The firm has a fifty day simple moving average of $36.55. Vor Biopharma Inc. has a 12 month low of $2.62 and a 12 month high of $65.80. The firm has a market cap of $198.65 million, a PE ratio of -0.11 and a beta of 2.07.

Vor Biopharma (NASDAQ:VOR) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Money Concepts Capital Corp lifted its holdings in Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock valued at $37,000 after acquiring an additional 26,535 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Vor Biopharma in the second quarter valued at about $66,000. OMERS ADMINISTRATION Corp purchased a new stake in Vor Biopharma during the first quarter worth about $100,000. Finally, Jane Street Group LLC acquired a new position in Vor Biopharma during the first quarter worth about $140,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Zacks Research cut Vor Biopharma from a “hold” rating to a “strong sell” rating in a research report on Monday, October 13th. Wall Street Zen cut Vor Biopharma to a “strong sell” rating in a research note on Saturday, June 28th. Wedbush reiterated an “outperform” rating on shares of Vor Biopharma in a research report on Thursday, June 26th. Baird R W raised shares of Vor Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 15th. Finally, HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Vor Biopharma in a research note on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Vor Biopharma presently has a consensus rating of “Hold” and an average price target of $77.83.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.